Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2026 07:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease

Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...
May 22, 2026 16:30 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III...
May 21, 2026 09:15 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of...
May 20, 2026 14:38 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system...
May 15, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
May 14, 2026 07:30 ET | Source: Biofrontera Inc.

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...
May 13, 2026 22:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for...
May 05, 2026 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval Steady-state pharmacokinetic findings provide mechanistic...
April 30, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
April 24, 2026 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare...